Phase III trial of dapagliflozin for hospitalised COVID-19 patients begins

The DARE-19 study will investigate the potential of the sodium-glucose cotransporter 2 inhibitor to delay disease progression and reduce the risk of clinical complications and death due to COVID-19 in patients who also have cardiovascular, metabolic or kidney risk factors.